August 5, 2011

Improved Rejection Prophylaxis With an Initially Intensified Dosing Regimen of Enteric-Coated Mycophenolate Sodium in De Novo Renal Transplant Recipients

.   .   

Previous studies have defined a therapeutic area under the curve for mycophenolic acid (MPA) in the early post-transplant period, although the majority of centers do not perform routine MPA monitoring. This paper presents results of a randomized controlled trial comparing an initial higher dose of MPA to standard dosing in patients treated with steroids, cyclosporine +/- an interleukin-2 receptor antibody. MPA exposure was higher in the high-dose arm, and rejection rates were lower. There were no differences in patient or graft survival, follow-up was only for six months, and these results may not apply to patients treated with tacrolimus or a lymphocyte-depleting antibody.

Related Articles:

Renal Transplantation

Comments are closed.